ABOUT US Mosaic Therapeutics is an oncology therapeutics company using advanced computational methods and next-generation cancer models to discover and develop novel targeted therapies. The company’s main mission is to tackle cancers with substantial unmet need by reinventing the traditional approach to target and drug discovery. Born out of pioneering research at the Wellcome Sanger Institute in collaboration with the Netherlands Cancer Institute, and anchored around a proprietary platform that has seen 20 years of fine-tuning and development, Mosaic has active programmes across a variety of oncology indications and disease biology pathways.
Location: United Kingdom, England, Hinxton
Employees: 11-50
Founded date: 2020
Investors 2
| Date | Name | Website |
| 11.11.2023 | Syncona Pa... | synconaltd... |
| 18.05.2023 | Cambridge ... | cic.vc |
Mentions in press and media 4
| Date | Title | Description |
| 04.04.2023 | Mosaic Therapeutics Closes $28M Series A Funding | Mosaic Therapeutics, a Cambridge, UK-based oncology therapeutics company, raised $28M in Series A funding. Backers included Syncona Investment Management, and Cambridge Innovation Capital. The company intends to use the funds to further adv... |
| 04.04.2023 | Cambridge Innovation Capital invests in Mosaic Therapeutics $28m Series A Funding | Cambridge Innovation Capital invests in Mosaic Therapeutics $28m Series A Funding Cambridge Innovation Capital (CIC), the venture capital investor focused on deeptech and life sciences businesses in the Cambridge ecosystem, has invested in ... |
| 04.04.2023 | Mosaic Therapeutics closes $28m series A funding and appoints Brian Gladsden as CEO | Company developing targeted oncology therapies spun out of world-leading research at the Wellcome Sanger Institute, in collaboration with the Netherlands Cancer Institute Syncona and Cambridge Innovation Capital invested Former Novartis SVP... |
| - | Mosaic Therapeutics | “Resolving cancer’s complexity” |